The FDA has approved Pfizer’s BEQVEZ, a gene therapy treatment for patients with moderate to severe haemophilia B, an inherited bleeding disorder affecting over 38,000 people globally. BEQVEZ helps increase production of factor IX (FIX), which is deficient in these patients, leading to impaired blood clotting. This approval will benefit patients who have experienced life-threatening bleeding and are currently taking FIX prophylaxis medication.
Critical Fortinet FortiClient EMS 0-Day Vulnerability Actively Exploited in the Wild
Fortinet has issued an emergency hotfix after security researchers disclosed a critical zero-day vulnerability in FortiClient EMS that is already being actively exploited by threat
